Immunology and Microbiology
Taenia solium
100%
Cestoda
76%
Cysticercosis
70%
Neurocysticercosis
61%
Tongue
57%
Prevalence
44%
Mass Screening
43%
Seroprevalence
33%
Enzyme-Linked Immunosorbent Assay
32%
ELISA
31%
Blood Level
28%
Albendazole
28%
Hymenolepis nana
28%
Severe Acute Respiratory Syndrome Coronavirus 2
28%
Bladder Wall
28%
Gene Expression Assay
28%
Cross-Reactivity
28%
Severe Acute Respiratory Syndrome
28%
Oncosphere
28%
Computer Assisted Tomography
28%
COVID-19
28%
Taenia saginata
28%
Pig
28%
Global Positioning System
28%
Transcriptome
28%
Protein Family
19%
Elution
14%
Stem Cell
14%
RNA Sequencing
14%
Subarachnoid Space
14%
Lipid Metabolism
14%
Metacestode
14%
Seropositivity
14%
Helminthiasis
14%
Immune Response
14%
Disease Burden
14%
Parasite Antigen
14%
Monoclonal Antibody
14%
Recombinant Antigen
14%
Oocyte Maturation
14%
Taenia
13%
Cell Line
11%
Serology
9%
Antigen-Antibody Interaction
9%
Cysticercus (Cestode Larva)
9%
Central Nervous System
9%
Feces
9%
Antibody Blood Level
9%
Larval Stage
9%
Echinococcosis
8%
Medicine and Dentistry
Taeniasis
45%
Cysticercosis
32%
Enzyme Linked Immunosorbent Assay
28%
Albendazole Sulfoxide
28%
Brain Imaging
28%
Antiparasitic Therapy
28%
Neurocysticercosis
28%
Combination Therapy
28%
Niclosamide
28%
Seroprevalence
28%
In Vitro
28%
Oncosphere
28%
Low and Middle Income Countries
28%
Anticonvulsant
28%
Therapeutic Management
28%
Bladder Wall
28%
Gene Expression Profiling
28%
Randomized Controlled Trial
21%
Adverse Event
20%
Protein Family
19%
Taenia solium
14%
Cell Signaling Pathway
14%
Arachnoiditis
14%
RNA Sequencing
14%
Subarachnoid Space
14%
Metacestode
14%
Cerebrospinal Fluid
14%
Lipid Metabolism
14%
Stem Cell
14%
Cross Sectional Study
13%
Drug Administration
12%
Lateral Flow Test
11%
Computer Assisted Tomography
11%
Cell Line
11%
Albendazole
10%
Central Nervous System
9%
Infection
9%
Epileptic Seizure
9%
Prevalence
9%
Etiologic Fraction
8%
Praziquantel
7%
Oxfendazole
7%
Cluster Randomized Trial
7%
Arm
7%
Non Communicable Disease
7%
Phenobarbital
7%
Patient Compliance
7%
Respiratory Distress
5%
Household
5%
Finger
5%
Pharmacology, Toxicology and Pharmaceutical Science
Taeniasis
28%
Antibiotics
28%
Acinetobacter
28%
Neurocysticercosis
28%
Randomized Controlled Trial
21%
Pseudomonas aeruginosa
17%
Herbal Remedy
14%
Carbamazepine
14%
Metacestode
14%
Cysticercosis
14%
Seizure
14%
Arachnoiditis
14%
Pseudomonas
11%
Imipenem
11%
Niclosamide
9%
Infection
9%
Cysticercus (Cestode Larva)
9%
Taenia solium
7%
Cohort Study
7%
Neurologic Disease
7%
Central Nervous System Infection
7%
Phenobarbital
7%
Non Communicable Disease
7%
Ageusia
5%
Anosmia
5%
Nose Obstruction
5%
Carbapenem Derivative
5%
Ceftriaxone
5%
Respiratory Distress
5%
Headache
5%
Meropenem
5%
Cephalosporin Derivative
5%
Ventilator Associated Pneumonia
5%
Ceftazidime
5%